Trials / Conditions / High-risk Neuroblastoma

High-risk Neuroblastoma

24 registered clinical trials studyying High-risk Neuroblastoma — 14 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma NCT06858501	Children's Oncology Group	Phase 2
Not Yet Recruiting	Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive C NCT07537400	Shaare Zedek Medical Center	Phase 2
Recruiting	Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma NCT07502287	Beijing Biotech	Phase 1 / Phase 2
Recruiting	PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma NCT07007117	Stephan Grupp MD PhD	Phase 1
Recruiting	Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma NCT06831552	Dana-Farber Cancer Institute	N/A
Active Not Recruiting	Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN） NCT07278674	Shanghai Children's Hospital	—
Recruiting	Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma NCT06803875	Roberto Chiarle	Phase 1 / Phase 2
Recruiting	Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors NCT06480526	St. Jude Children's Research Hospital	—
Recruiting	Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for NCT06607692	Fundación de investigación HM	Phase 1 / Phase 2
Withdrawn	PediCARE Health Equity Intervention in High-Risk Neuroblastoma NCT06335745	Dana-Farber Cancer Institute	N/A
Withdrawn	Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma NCT06182410	University of California, San Francisco	Phase 2
Recruiting	N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastom NCT06528496	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma NCT06057948	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma NCT05650749	Stephan Grupp MD PhD	Phase 1
Recruiting	GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 NCT05130255	Y-mAbs Therapeutics	Phase 1
Completed	Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participan NCT05373901	BeiGene	Phase 1
Recruiting	Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primar NCT05272371	Jagiellonian University	Phase 1
Completed	Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or R NCT04751383	National Cancer Institute (NCI)	Phase 1
Recruiting	High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) NCT04221035	Gustave Roussy, Cancer Campus, Grand Paris	Phase 3
Active Not Recruiting	Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With NCT03794349	Children's Oncology Group	Phase 2
Active Not Recruiting	Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Ne NCT03786783	National Cancer Institute (NCI)	Phase 2
Completed	Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant NCT01041638	National Cancer Institute (NCI)	Phase 3
Unknown	Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma NCT03061656	Samsung Medical Center	Phase 2
No Longer Available	Naxitamab and GM-CSF in People With Neuroblastoma NCT04501757	Memorial Sloan Kettering Cancer Center	—